Acetyl Tetrapeptide3
Description
Anti-edema peptide for periorbital area. Mechanism: ACE inhibition — dose-dependent inhibition of angiotensin-converting enzyme reduces microvascular pressure; reduced vascular permeability — decreases endothelial cell permeability, inhibiting interstitial fluid leakage; anti-glycation — protects collagen and SOD from fructose-mediated glycation, preserving elasticity. Strengthens capillary walls, reduces dark circle appearance.
Function
Properties
Regulatory Status
Acetyl Tetrapeptide-5 has triple-mechanism clinical substantiation for periorbital puffiness and dark circles: ACE inhibition, reduced vascular permeability, and anti-glycation, with in-vivo studies confirming in-vitro findings and no safety concerns.
No specific FDA restrictions. No pre-market approval required under MoCRA.
Ratings
Identifiers
No registry identifiers available for this ingredient.